Combi-chem & High Throughput Screening to Gain Traction in Drug Discovery

San Francisco, California, July 20, 2017:The growing popularity of combinatorial chemistry and the rising application of high-speed analog chemistry in various drug discovery processes are the key factors boosting rapid evolution of the combi-chem and high-throughput screening market. The rising prominence of high-throughput synthesis of small molecule libraries and peptides in numerous drug discovery researches is a crucial trend driving the growth of the market. A new report penned by TMR Research, titled “Combi-chem & High Throughput Screening Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025, offers an elaborate assessment of such trends and factors impacting the dynamics of the market.

The research provides in-depth insights into the key drivers and restraints, notable trends, emerging technologies, lucrative opportunities, major technological advancements, and competitive landscape scenario. The growing utility of a large number of small molecule libraries in the drug discovery processes, along with their parallel synthesis, has led to a burgeoning demand for combi-chem and high-throughput screening in therapeutics and diagnostics. Over the past few years, the generation of small molecule libraries has gained increased significance in the production of large libraries vital in the area of targeted therapies. This is expected to accentuate the combi-chem and high-throughput screening market.

The increasing prevalence of infectious diseases and various types of cancer and the growing demand for targeted therapies in various developing and developed regions are some of the key factors boosting the market. The growing application of combi-chem and high-throughput screening in the discovery of anti-cancer therapies is expected to catalyze the market in the coming years. In addition, the demand for natural product biosynthesis for the creation of libraries among pharmaceutical players has propelled the demand for combi-chem and high-throughput screening. Furthermore, the increasing adoption of automation to eliminate piecemeal experimental works among researchers has positively impacted the market.

However, the lack of technical expertise and the high investment required for combi-chem and high throughput screening equipment are likely to hinder the global combi-chem and high-throughput screening market to an extent. Nevertheless, the growing application of combinatorial chemistry and high-throughput screening in preclinical discoveries with rapid turnaround times bodes well for the market.

Regionally, North America and Europe are prominent markets for the combi-chem and high-throughput screening. The growth of these regional markets is driven by the increasing prevalence of several chronic and infectious diseases and the rising incidence of cancer in several countries. In addition, constant government initiatives to spur investments in research and development of targeted therapies have accentuated the regional markets.

Meanwhile, Asia Pacific is expected to offer abundant opportunities for a number of biotechnologies and pharmaceutical companies over the forecast period. The region is anticipated to offer large untapped opportunities to capitalize on. Constant advancements in healthcare infrastructure and substantial governmental funding for disease prevention in several developed and developing nations have bolstered the uptake.

Key players vying for a significant share in the combi-chem and high-throughput screening market include Pfizer, Inc., Merck & Co., Sanofi S.A., Abbott Healthcare, and AstraZeneca plc.